Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database

Survival outcomes following primary tumor resection for patients with incurable metastatic colorectal carcinoma: Experience from a single institution

“…Our key finding of the association of PTR with improved OS, regardless of chemotherapy administration, is interesting. This result is in consistent with other retrospective studies and meta‐analyses that have shown a survival benefit of PTR. In our cohort the decision for elective palliative PTR was based on multidisciplinary tumor board discussions.…”

“…The managements of patients with unresectable disease at diagnosis have not been well defined. For patients eligible for palliative chemotherapy, median OS ranges from 11.4 to 16.4 months post‐initiation of chemotherapy . Most do not require surgical intervention (i.e., primary tumor resection or diversion surgery) for treating primary tumor complications .…”

“…For patients eligible for palliative chemotherapy, median OS ranges from 11.4 to 16.4 months post-initiation of chemotherapy. [7][8][9][10][11] Most do not require surgical intervention (i.e., primary tumor resection or diversion surgery) for treating primary tumor complications. 7 It is unclear whether surgery should be confined to patients who are symptomatic from a primary tumor or if it could be expanded to include patients who have asymptomatic, resectable primary tumors.…”

The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor

“…Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide [ 1 ], and approximately 25% of patients with CRC have distant metastasis at the initial diagnosis [ 2 ]. In the era of cytotoxic drug combinations and molecular targeting agents, the integration of surgery and effective systemic chemotherapy has emerged as a new strategy for prolonging survival of patients with metastatic colorectal cancer (mCRC) [ 3 – 7 ]. However, in most cases the disease is not curable.…”

Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?

“…A recent individual patient data analysis of trials in mCRC showed an improved survival in synchronous mCRC patients if the primary was resected. 12 Such analyses are open to bias because the reasons that resection is not performed are not available. Hence, presently, it’s not known whether the primary should be resected or not.…”